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Cancer gene therapy has been one of the most exciting areas of therapeutic research in the past decade. In this review, we discuss
strategies to restrict transcription of transgenes to tumour cells. A range of promoters which are tissue-speciﬁc, tumour-speciﬁc, or
inducible by exogenous agents are presented. Transcriptional targeting should prevent normal tissue toxicities associated with other
cancer treatments, such as radiation and chemotherapy. In addition, the speciﬁcity of these strategies should provide improved
targeting of metastatic tumours following systemic gene delivery. Rapid progress in the ability to speciﬁcally control transgenes will
allow systemic gene delivery for cancer therapy to become a real possibility in the near future.
INTRODUCTION
Genetherapyisthetransferofexogenousgenes,called
transgenes, into the somatic cells of a patient to obtain a
therapeutic eﬀect. Initially, gene therapy was viewed as an
approach for treating hereditary diseases, but its potential
role in the treatment of acquired diseases such as cancer is
now widely recognised. In theory, gene therapy oﬀers the
potential for enormous improvements in the targeting of
cancer therapy, but it is clear that this has not yet been
achieved, although early trials are promising.
One of the main goals for all cancer therapies is the
selective targeting and killing of tumour cells, thereby in-
creasingthetherapeuticratio.Bothchemotherapyandra-
diotherapy induce dose limiting normal tissue toxicities,
whichreducetheirclinicaleﬀectiveness.Cancergenether-
apy has the advantage that normal tissue toxicity might
be avoided if suitable strategies can be employed to tar-
get the therapeutic transgene directly to tumour cells; an
outcome that conventional therapeutic approaches have
failed to achieve.
To date, clinical trials have focused on the delivery of
genes directly to the tumour site by intratumoural injec-
tion using both viral and nonviral delivery agents, thereby
largelyavoidingnormaltissues.However,thegoalofmost
cancer gene therapy is to be able to administer a suitably
packaged transgene systemically and achieve a high level
of tumour targeting. This will be important for targeting
the majority of tumours, that are not accessible for di-
rect injection, and to ensure adequate distribution of the
transgene throughout the tumour mass. The blood sup-
ply still oﬀers the best opportunity to do this. Systemic
delivery of transgenes would also allow targeting of both
the primary tumour and metastatic deposits, which must
be controlled if therapy is to be successful. A number of
strategies are now being developed to target both viral
and nonviral delivery agents to tumour cells. These in-
clude exploitation of natural viral tropisms, such as those
exhibited by adenoviruses to target lung epithelium; re-
targeting viruses using a bispeciﬁc molecule to simultane-
ously block native receptor binding, redirecting virus to
a tissue-speciﬁc receptor; genetically modifying the virus
to ablate native receptor interactions and incorporating
a novel ligand into one of the virus’ coat proteins; using
tissue-speciﬁc ligands or monoclonal antibodies incorpo-
rated onto the surface of liposomes to direct them to tar-
get cells. A detailed description of these targeted delivery
strategies, lies beyond the scope of this review(forreviews
covering this area see references [1, 2, 3, 4]).
As well as controlling the delivery of the therapeutic
gene to the tumour tissue, controlled regulation of trans-
gene expression is now playing a major role in targeted
cancer gene therapy strategies. Indeed, by combining tar-
geted delivery with tumour-speciﬁc expression, the level
of transgene product in nontarget normal tissues, com-
pared with that in tumours, can be greatly reduced. The
purpose of this review is to focus on transcriptional tar-
geting of transgenes, which will undoubtedly be an essen-
tial component of systemic cancer gene therapy.
TRANSCRIPTIONAL CONTROL OF EXPRESSION
In the last decade, it has become increasingly clear
that gene expression is regulated by a complex inter-
play of factors that function in a cell-type-speciﬁc man-
n e rt op r o d u c ed i v e r s ee ﬀects. These subtleties arise
from the balance of tissue-speciﬁc transcriptional con-
trol elements present in the various cell types, for ex-
ample, hepatic, melanocyte, neuronal, and erythroid or
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Figure 1. The use of speciﬁc tissue/tumour/inducible promoters to allow targeted transcription in tumour cells. Tissue-speciﬁc,
tumour-speciﬁc, or inducible (eg, by radiation, drugs, etc) promoters can limit gene expression to target cells which express a speciﬁc
transcription factor, or in which the transcription factors are activated exogenously.
in diseased states, or as a result of being exposed to an
unfavourable tumour-associated microenvironment, for
example, hypoxia. These cis-acting elements can be har-
nessed to drive the transcription of a therapeutic gene in
a tissue- or tumour-speciﬁc manner (Figure 1). The use
of tissue-speciﬁc cellular promoters to restrict transgene
expression usually results in constitutive expression in the
target tissue. However, for some therapeutic strategies, it
will be preferable to regulate the duration and level of ex-
pression exogenously. This may be achieved by the use of
cellular promoters that are preferentially activated under
certainconditionstodrivetransgeneexpressioninthetar-
get cell population. Research has focused on promoters
induced by ionising radiation, heat, and small molecules.
The use of tissue- and tumour-speciﬁc and exogenously
controlled inducible promoters will now be discussed, as
well as novel molecular adaptations of these promoters to
strengthen gene expression. However, because the num-
ber of promoters that have been used for transcriptional
targeting of transgenes for cancer gene therapy is very
large, it is not feasible to discuss all of these in detail. The
availabledatatodatewillthereforebepresentedinaseries
of tables.
TISSUE-SPECIFIC PROMOTERS
Transcriptional targeting utilising tissue-speciﬁc pro-
moters exploits genes that are switched on only in certain
tissues. A list of tissue-speciﬁc promoters currently being
used in cancer gene therapy is given in Table 1. One of the
main limitations of this type of promoter is that trans-
gene expression may lead to cytotoxic eﬀects in normal
as well as tumour tissue derived from that same cell type.
Therefore, the use of such promoters must be restricted to
tissues in which damage is not critical for the survival of
the host, for example, prostate, melanocytes, or thyroid.
If the tissue/organ is critical, then the transgenes must be
delivereddirectlytothetumoursitetopreventnormaltis-
suetoxicityorbedeliveredwithretroviruseswhichareless
eﬃcient at infecting nondividing slowly proliferating nor-
mal tissues, such as the liver.
Melanocyte-restrictedexpression
The use of tissue-speciﬁc promoters was pioneered by
Vile and Hart in 1993, with the use of the tyrosinase pro-
motertotargetmelanocytes/melanomas.Melaninbiosyn-
thesis is restricted to melanocytes, partly, as a conse-
quence of transcriptional regulation of gene products,
such as tyrosinase or tyrosinase-related protein 1, in-
volvedinthisbiochemicalpathway.VileandHartdemon-
strated that small elements of the 5  ﬂanking regions of
these two genes could drive reporter gene expression in
murine and human melanoma cell lines in vitro and in
vivo, but they could detect only low level expression in
other cell types in vitro and no expression in Colo 26
tumours grown in vivo following direct injection of the
transgenes [5]. They went on to demonstrate eﬃcacy in
vivo using the herpes simplex thymidine kinase (HSV-112 T. Robson and D. G. Hirst 2003:2 (2003)
Table 1. Tissue-speciﬁc promoters used in cancer gene therapy.
Promoter Target tissue/tumour Reference
Tyrosinase Melanocytes/melanoma [5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18]
Prostate-speciﬁc antigen (PSA) Prostate
[19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33]
Prostate-speciﬁc membrane antigen
(PSMA)
Prostate/also targets vascular
endothelium of other tumours [31, 34, 35, 36]
Probasin Prostate [28, 37, 38, 39, 40, 41]
Human glandular kallikrein (hK2) Prostate [25, 37, 38, 42]
Glial ﬁbrillary acidic protein (GFAP) Glial/glioma [43, 44, 45, 46, 47, 48, 49, 50, 51]
Myelin basic protein (MBP) Glial and astocytes/glioma [43, 44, 52, 53, 54, 55]
Myelin proteolipid protein Glial/glioma [43, 44]
Neural speciﬁc enolase Neuronal/SCLC [48, 56]
Neuronal speciﬁc synapsin 1 Neuronal [57, 58]
Ncx/Hox11L.1 Neuralcrestderivedcells/neurobalstoma [59]
Albumin Liver/hepatocellular carcinoma [60, 61, 62, 63, 64, 65, 66]
Surfactant protein B Type II alveolar and bronchial cells/lung
cancer [67, 68]
Thyroglobulin Thyroid/thyroid carcinomas [69, 70, 71, 72, 73]
Ovarian-speciﬁc promoter Ovarian [74, 75]
tk)/gancyclovir (GCV) combination, which gave a signif-
icant tumour growth delay following intratumoural in-
jection of the tyrosinase-driven constructs and decreased
metastatic potential in mice injected with melanoma
cells expressing these constructs following treatment with
GCV [6]. In a separate study, tissue-speciﬁc expression
of IL-2, IL-4, and GM-CSF was also seen in vitro and
in vivo [7]. As an extension to this work, retroviruses
were developed containing the murine tyrosinase pro-
moter to achieve transcriptionally targeted expression of
HSV-tk or IL-2 genes [8, 9]. Antitumour eﬃcacy and tis-
sue speciﬁcity were observed after intratumoural and IV
delivery using localised and metastatic melanoma mod-
els [7]. Other studies have demonstrated antitumour ef-
ﬁcacy using both retrovirus [10] and cationic liposomes
[11] to achieve tyrosinase driven expression of cytosine
deaminase (CD), which in turn catalyses the conversion
of the nontoxic prodrug 5-ﬂuorocytosine (5-FC) to 5-
ﬂuorouracil (5-FU). Adenoviral delivery of the murine
tyrosinase promoter, introduced into the E1 region, has
been used to drive melanoma-speciﬁc expression of the
reporter gene β-galactosidase [12]. Both studies showed
eﬀective transcriptional targeting. More recently, tissue-
speciﬁcelementsofthetyrosinasepromoterhavebeenin-
corporated into more elaborate DNA constructs, that in-
corporate either a second tumour-speciﬁc promoter, cy-
clin A [13] for added speciﬁcity, or elements to help in-
crease tyrosinase promoter expression [14]. As an exten-
sion to this, both targeted delivery and transcriptional
targeting of melanoma cells via the tyrosinase promoter
were combined in one study. Anionic liposomes carrying
a peptide ligand for targeting α-v-β3-integrin receptors,
commonly upregulated on malignant melanoma cells,
were used in this instance for the transductional target-
ing [15] .T h e s em o r ee l a b o r a t ec o m b i n e da p p r o a c h e sw i l l
be discussed in detail later as future perspectives.
Prostate-speciﬁcexpression
Another well-characterised tissue-speciﬁc promoter is
that of prostate-speciﬁc antigen (PSA). Prostate-speciﬁc
antigen is expressed predominantly in the prostate and
is transcriptionally upregulated by androgens. Pang et al
[19] demonstrated that elements from the 5  region of
this gene can drive reporter gene expression in the PSA-
producing cell line, LNCaP, but not in the nonproduc-
ing tumour cell lines, DU145 and PC-3, nor in renal or
breast cancer cell lines. Tumour cell growth was inhib-
ited when the PSA promoter was used to drive expres-
sion of antisense constructs targeting DNA polymerase
α and topoisomerase α in prostate tumour cell lines,
but not in cell lines of any other tumour [20]. In ad-
dition, a replication-competent adenovirus, CN706, has
been developed with a selective toxicity for PSA-positive
prostate cancer cells, using minimal enhancer/promoter
constructs derived from the 5  ﬂank of the PSA gene, to
drive the E1A gene [21]. A single intratumoural injection
of the virus destroyed large LNCaP tumours and abol-
ished PSA production in mice. Gotoh et al [22]h a v ed e -
veloped an attenuated adenovirus which expresses HSV-
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promoter was active in both androgen-dependent and in-
dependent PSA-producing prostate cancer cells in vitro,
and in prostate tumours in castrated hosts. Chimeric con-
structs which have also been engineered improved the ac-
tivity and speciﬁcity of the PSA enhancer. Importantly,
intravenous delivery of adenoviral constructs, with either
duplication of the enhancer core or insertion of tandem
copies of the proximal androgen response elements, not
only showed enhanced activity and inducibility but also
retainedtissuediscriminationforhumanLAPC-9tumour
xenografts [23]. Constructs utilising PSA promoter ele-
ments have also been developed to drive the expression of
the sodium iodide transporter to concentrate radioiodine
in the prostate [24]. They have also been used to increase
the expression of nitroreductase or CD allowing sensiti-
sation of prostate cells to the prodrugs, CB1954 [25]o r
5-FC, respectively [76]. PSA promoter driven transgenes
have also been delivered using an HIV-1-based lentiviral
vector [26] and liposomes [27].
Promoters of prostate-speciﬁc genes other than PSA
are now being utilised. Prostate-speciﬁc membrane anti-
gen (PSMA) is a type-2 membrane protein expressed in
virtually all prostate cancers and their metastases. More-
over, unlike PSA, PSMA expression is upregulated by
androgen deprivation. These advantages make PSMA a
useful target for advanced prostate cancer therapy, espe-
cially in combination with conventional hormonal treat-
ment. O’Keefe et al [34] have determined the most ac-
tive regions of the PSMA enhancer and revealed a 1.6-
kbp region which was active in driving prostate-speciﬁc
CD expression, sensitising cells in vitro to 5-FC more
than 50-fold compared to control cells. Furthermore, C4-
2 prostate tumours grown in nude mice were eliminated
by 5-FC when CD expression was induced by the PSMA
promoter/enhancer [35]. This type of promoter will be
particularly useful for patients who have undergone an-
drogen ablation therapy and are suﬀering from a relapse
of the disease.
Human glandular kallikrein (hK2) and PSA are re-
lated members of the human kallikrein gene family, how-
ever, unlike PSA whose expression displays an inverse cor-
relation with prostate cancer stage and grade, hK2 is up-
regulated in higher grade and stage of the disease. Yu et
al [37] identiﬁed an androgen-dependent and prostate-
speciﬁc enhancer located between −3.4a n d−5.2kbpup-
stream of the hK2 transcription start site. A replication-
competent adenovirus was constructed, CV763, in which
the E1A gene was driven by the hK2 enhancer/promoter.
S p e c i ﬁ c i t yf o rp r o s t a t et u m o u r si nv i v ow a si m p r e s -
sive. More recently, a recombinant adenovirus express-
ing EGFP under the control of a triplicate hK2 en-
hancer/promoter led to robust tumour-restricted EGFP
expression [38].
Probasin is another prostate-speciﬁc promoter, which
has been used by many groups for transcriptional tar-
geting of therapeutic transgenes. Steiner et al [28] used
probasin to drive the expression of the LacZ reporter gene
in a canine model following intraprostatic injection. They
were able to demonstrate that, although adenovirus was
detected in other tissue, lacZ mRNA could be detected
by RT-PCR only in the prostate and not in other tis-
sues. A small potent composite rat probasin promoter
has been developed, ARR(2)PB, which is both androgen-
and glucocorticoid-inducible [39]. When used to drive
cell cycle-independent caspases, in an adenoviral system,
it can lead to apoptosis in prostate cancer xenografts, but
not in xenografts of other tumours, when the dimeric
ligand AP20187 is delivered to trigger caspase activation
[77].Moreimportantly,systemicdeliveryofasimilarade-
novirus, utilising the ARR(2)PB composite promoter to
drive BAX expression, revealed no toxicity in the liver,
lung, kidney, or spleen, but resulted in highly speciﬁc cy-
totoxicity in the prostatic cancer cell line LNCaP [40].
Lastly, a tumour-speciﬁc rather than prostate-speciﬁc
promoterfromtheosteocalcingenehasshownaconsider-
ablepromiseintargetingprostatecancerbonemetastases.
This will be discussed in the next section.
Glial-restrictedexpression
A number of tissue-speciﬁc promoters have now been
tested for targeting of gliomas. In 1993, Miyao et al [43],
described 2.5kbp, 1.3kbp, and 1.5kbp 5  ﬂanking regions
of the mouse glial ﬁbrillary acidic protein (GFAP) gene,
myelin basic protein (MBP) gene, and myelin proteolipid
protein (PLP) gene, respectively, which conferred speci-
ﬁcity for glial cells. Following retroviral delivery, tran-
scription was initiated more eﬀectively in glioma cells
via the MBP promoter where the HSV-tk transgene sen-
sitised cells to gancyclovir in both murine and human
glioma cells [44]. GFAP promoter driven expression of
HSV-tk and therapeutic eﬃcacy for gliomas was demon-
strated by other groups [45, 46]. The RL1 variant her-
pes simplex virus 1 (HSV-1) has also been engineered to
target intracerebral tumours of glial and astrocyte origin
by using the GFAP promoter. These viruses, 1774 and
1775, showed high levels of β-galactosidase expression
speciﬁcally in astrocytes following intracerebral inocula-
tion [47]. Replication-defective adenoviral vectors have
alsobeenengineeredtocontaineithertheGFAPpromoter
or the neuronal speciﬁc enolase promoter [48, 49]. Im-
portantly, in the Morelli study, Fas ligand (FasL) trans-
gene expression and induced-toxicity following IV de-
livery were restricted to glial tissue, unlike the noncell-
type-speciﬁc CMV-driven viruses that induced acute liver
haemorrhage with hepatocyte apoptosis. Tight control
of transgene expression was therefore achieved follow-
ing systemic delivery. In the Chen study, a repressible
adenovirus was developed by driving expression of a
tetracycline-controlled transactivator. This was the ﬁrst
glial-speciﬁc gene delivery system that allowed for repres-
sion of ectopic gene expression. More recently, an elegant
liposomal delivery system has been developed; it incor-
porates both transport across the blood brain barrier fol-
lowing IV administration of a targeting ligand such as the
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receptor, and restricted expression to glial cells by the
use of the GFAP promoter. This particular study demon-
strates that tissue-speciﬁc gene expression in brain is pos-
sible after IV administration of a nonviral vector com-
bined with gene targeting technology and glial-speciﬁc
promoters [50]. Shinoura et al [52, 53, 54] have used
the MBP promoter to drive expression of two apoptosis-
related genes, BAX and caspase 8, selectively, in glioma
cellsbothinvitro,andinvivousingadenoviruses.Massive
apoptosis was seen in glioma cells only, demonstrating ef-
fective tissue speciﬁcity and good antitumour eﬃcacy was
observed in vivo.
As well as promoters that can target gliomas, a
promoter that could be useful in targeting neuroblas-
tomas has also been described. The human NCX gene,
is a homologue of the murine neural crest homeobox
(Ncx/Hox11L.1) gene, whose expression is restricted to
a subset of neural crest-derived tissues. A 1.7-kbp frag-
ment upstream showed preferential promoter activity in
neuroblastoma cells and when linked to the HSV-tk gene
caused increased sensitivity to gancyclovir [59]. The reg-
ulatory region of this gene may therefore be useful for
neuroblastoma-speciﬁc gene therapy.
Liver-speciﬁcexpression
The enhancer/promoter of the albumin gene is the
onlytissue-speciﬁcpromoterthathasbeenshowntopref-
erentially target liver cells. The ﬁrst demonstration of ef-
ﬁcacy using this promoter was by Kuriyama et al [60].
When this promoter was delivered using a retrovirus,
w h i c hi se ﬃcient only in dividing cells, β-galactosidase
expression was restricted to hepatoma cell lines in vitro.
When this retrovirus was injected via the spleen or di-
rectly into the liver, gene expression was observed only in
dividing heptocytes in partially hepatectomised mice, but
notinnondividinghepatocytesinnormalmice.Theseau-
thors went on to show that the susceptibility of murine
and rat hepatocellular carcinoma (HCC) cells, infected
with retroviruses expressing HSV-tk under the control of
the albumin promoter, were 100-fold more sensitive to
gancyclovirthannon-HCCcells.Systemicgancyclovirad-
ministration resulted in complete regression of retroviral-
infected HCC cells and signiﬁcant inhibition of tumour
growth even when only 5% of the cells were infected
with retrovirus [61]. The albumin promoter has also been
used to develop a retrovirus expressing the TNF-α,I L - 2 ,
and IL-3 genes [62, 63], an adenovirus expressing HSV-
tk [64, 65] and a replication-competent herpes simplex
virus, HSV G92A [66].
Thyroid-speciﬁcpromoters
Thyroid cancer is a disease with a relatively good
prognosis, but about 30% of the tumours dediﬀerentiate
and may ﬁnally develop into highly malignant anaplas-
tic thyroid carcinomas which are inaccessible to standard
therapeutic procedures such as radioiodine therapy and
thyroxine-mediated thyrotrophin suppression. Several
gene therapy strategies are now available to target ther-
apeutic genes to thyroid tissues using tissue-speciﬁc pro-
moters. Zeiger ﬁrst described the use of the thyroglobulin
(TG) gene promoter for the selective targeting of thyroid
cell lines. Nearly, 100% of thyroid carcinoma cells treated
with an adenovirus expressing HSV-tk under the control
of a TG promoter were killed by GCV compared to only
5% of control cells [69] .Ar e tr o vi ru sc a rryi n gH S V - tk un-
der the control of the TG promoter also showed preferen-
tialGCVtoxicityformalignantratthyroidcarcinomacells
compared to a normal rat thyroid cell line in vitro and
in vivo [70]. Furthermore, systemic delivery of an ade-
novirus expressing thyroglobulin-driven HSV-tk did not
induce luciferase activity in the liver or spleen, indicating
that TG does not induce luciferase expression in non-TG
producing tissues [71]. In addition, transfer of the HSV-
tk gene driven by the TG promoter following administra-
tion of GCV is speciﬁcally cytotoxic to thyroid cells [71].
In order to address the issue that most poorly diﬀerenti-
ated and anaplastic thyroid carcinomas have lost the abil-
ity to express the TG gene through loss of the thyroid
transcription factor-1 (TTF-1), TTF-2, or Pax 8, Shimura
et al infected thyroid cells with both adenoviruses ex-
pressing TTF-1 and adenoviruses carrying HSV-tk driven
by the thyroglobulin promoter [72]. Cotransduction per-
mitted 90% cytotoxicity in thyroid carcinoma cells lack-
ing this transcription factor and normally unable to ex-
press the TG gene. A putative enhancer element for the
TG gene has also been recently identiﬁed which appears
to increase the TG promoter activity and speciﬁcity for
thyroid cells. Interestingly, the TG promoter is also be-
ing used to target feline thyroid disease and neoplasia
by selectively increasing expression of the nitroreductase
geneallowingsubsequentactivationofaprodrug,CB1954
[73].
Several other novel tissue-speciﬁc genes have been
used to target tumours in a tissue-speciﬁc manner, al-
though only one or two reports are available. These in-
clude an ovarian-speciﬁc promoter, OSP-1, a 462-bp se-
quence that is a part of a retrovirus-like element speciﬁ-
c a l l ye x p r e s s e di nr a to v a r y[ 74]. The expression of HSV-
tk under the control of this promoter signiﬁcantly sen-
sitised ovarian cancer xenografts (OVCAR) to GCV fol-
lowing delivery with a cationic lipid [75]. In addition,
the promoter for surfactant protein B (SPB), whose ac-
tivity is restricted to adult type II alveolar epithelial cells
and bronchial epithelial cells, has been used to target both
replication-deﬁcient [67] and -competent adenoviruses
by replacement of the E4 promoter [68]. This promoter
showed good speciﬁcity for bronchial cancer cells in vivo.
TUMOUR-SPECIFIC PROMOTERS
Ideally, tumour-speciﬁc promoters should be highly
active in tumour cells and have little or no activity in
normal cells. Harrington et al [78] elegantly split this
vast group of promoters into subgroups depending on2003:2 (2003) Transcriptional Targeting in Cancer Gene Therapy 115
their discrete characteristics and for the purpose of this
review this convention will be applied. Tumour-speciﬁc
promoterscanbedescribedas(1)cancer-speciﬁcpromot-
ers, that is, speciﬁc for the malignant process, but show-
ing no tissue speciﬁcity (2)tumour-type-speciﬁc promot-
ers,thatis,oncofoetalrelatedwithtissuespeciﬁcity(3)tu-
mour microenvironment-related promoters, that is, pro-
moters which respond to the tumour microenvironment
and physiology, for example, hypoxia and glucose regu-
lated (4) tumour vasculature-related promoters, that is,
promoters which are more active in the tumour vascula-
ture rather than normal vasculature.
Cancer-speciﬁcpromoters
One of the main obstacles to current cancer therapies
isthelackoftumourspeciﬁcity.Targetinggeneexpression
speciﬁcally to tumour cells is therefore one of the most
important goals of cancer gene therapy strategies. A com-
mon problem with the use of the tissue-speciﬁc promot-
ers which were described in the previous section, is that
transgene expression can also occur in the normal tissue
and whilst some tissue damage may be acceptable in cer-
tain organs, in other organs such as brain, liver, and so
forth, it could be catastrophic. There is probably only one
gene, telomerase, that can be genuinely classiﬁed as can-
cer speciﬁc and whose promoter is being used to drive the
expressionoftransgenesselectivelyinawidevarietyoftu-
mour cells.
Telomerase activation is considered to be a critical
step in cancer progression because of its role in cellu-
lar immortilisation. Approximately 90% of human can-
cers possess active telomerase, whereas normal somatic
tissues have either much lower or undetectable activity
[79, 80, 81]. Human telomerase activity depends on the
presence of both the RNA subunit (hTR) and the catalytic
protein component (hTERT) [82]. For both genes there is
ac l e a rd i ﬀerential expression between normal and malig-
nant cells. A number of studies have used these two pro-
moters to drive transgene expression for therapeutic ben-
eﬁt. Pan and Koeneman [83] ﬁrst described the use of the
hTERT promoter in a retroviral system and combined it
with a Cre/loxP site-speciﬁc recombination system to al-
low the killing of p53-negative tumour cells while spar-
ing normal wild-type cells. Since then, a host of papers
have reported the use of both promoters in several dif-
ferent tumour types in combination with several diﬀer-
ent transgenes. Bladder and liver tumour cell lines were
targeted using both hTR and hTERT to drive expression
of the diphtheria toxin A chain gene [84]. The glioma
cell line, UVW, was targeted using the hTR promoter to
drive expression of the noradrenaline transporter gene
(NAT) where a 17-fold enhancement of the radionuclide
[131]meta-iodobenzylguanidine uptake was reported re-
sultingincompletesterilisationoftumourspheroids[85].
Gliomas were also the target for hTERT-driven expression
of Fas-associated protein with death domain (FADD) or
rev-caspase-6. FADD is a protein which induces apopto-
sis in cells regardless of Fas expression on the cell sur-
face and rev-caspase 6 induces apoptosis independent
of initiator caspases. Subcutaneously implanted human
gliomas treated with this construct were signiﬁcantly re-
d u c e di nv o l u m ec o m p a r e dt oc o n t r o lt u m o u r s[ 86, 87,
88]. More recently, the apoptotic pathway was success-
fully targeted both in human tumour xenograft and syn-
geneic mouse UV-2237m ﬁbrosarcomas, using Bax as a
transgene, driven by the hTERT promoter [89, 90]. In a
suicide gene therapy approach, hTERT was also used to
drive expression of HSV-tk in an osteosarcoma xenograft
model following intratumoural injection. Targeted de-
livery using this approach avoided the liver toxicity ob-
served using a CMV driven construct following GCV ad-
ministration. Finally, Keith’s group [91]t e s t e dh T Ra n d
hTERT in a panel of 10 cell lines consisting of lung, colon,
ovarian, bladder, and cervical origin, demonstrating the
truly“cancerspeciﬁc”natureofthesepromoters.ThehTR
promoter appeared to have the superior activity in the
telomerase-positive cell lines and when used to drive the
nitroreductase gene to increase the activation of the pro-
drug, CB1954, in two xenograft models, it showed even
betterantitumoureﬀects(upto97%reductionintumour
volume) than a CMV-driven construct [91]. These pro-
moters clearly have a real potential in targeting a wide
range of diﬀerent tumour types.
Tumour-type-speciﬁcpromoters
Certain types of tumour often overexpress genes
of oncofoetal origin that are silent in normal tissue.
The most well-characterised promoters of these tumour-
speciﬁc genes are the carcinoembryonic antigen (CEA)
and α fetoprotein (AFP), which are expressed in adeno-
carcinomas and hepatocellular carcinomas, respectively.
There are also many other genes that are overexpressed
in certain tumour types and, as such, their promoters are
beingutilisedfortranscriptionalregulationoftherapeutic
genes.
CEA
The CEA promoter is active in a proportion of breast,
lung, colorectal, and pancreatic cancers. The 5  promoter
sequences have been analysed and identiﬁed by reporter
gene assays and have lead to high-level selective expres-
sion of transgenes in CEA-positive cell lines [92]. The
C E Ap r o m o t e rh a sb e e nu s e dt od r i v eC De x p r e s s i o n
[92, 93, 94], HSV-tk [95, 96, 97, 98, 99], BAX [100], and
mammalian degenerin, a sodium ion channel gene, over-
expression of which leads to sodium inﬂux and cell burst-
ing [101]. Importantly, CEA appears to be truly selective
for tumour tissues in animal models as several reports
have not detected transgene expression or related toxici-
ties following systemic delivery of these constructs via tail
vein injection [98] or intraperitoneally [94]. Although a
signiﬁcant number of studies have shown that the CEA
promoter is eﬀective for selectively targeting tumour cells,
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truly signiﬁcant in vivo antitumour eﬀects possibly be-
cause of the low activity of the promoter. More recently,
several studies have made use of a Cre recombinase/lox
P system [102, 103, 104] or a GAL4 regulatory system
[100], both of which signiﬁcantly increased transgene ex-
pression by up to 100 fold, while maintaining tumour
speciﬁcity. These strategies will be discussed in more de-
tail later. Finally, Qiao et al [105] constructed an aden-
ovirus containing a binary promoter system with a CEA
promoterdrivingatranscriptionactivator,whichthenac-
tivates a minimal promoter to express HSV-tk.I m p o r -
tantly, in vivo dose-escalation studies demonstrated sig-
niﬁcantly reduced toxicity following intravenous admin-
istration of this construct and provide a proof of principle
for the powerful enhancement of a weak promoter for ef-
fective tumour-restricted gene expression.
AFP
The α-fetoprotein gene is normally expressed in foetal
liver and is transcriptionally silent in adult liver. It is also
expressed in around 70% of the hepatocellular carcino-
mas and its promoter has been used extensively to drive
transgene expression for targeting these tumours. Stud-
ies have clearly shown that transgene expression is re-
stricted to tumours that overexpress AFP and that trans-
geneexpressionislesseﬃcientintumourswithlowerAFP
levels. A variant 0.3-kbp promoter has also been devel-
oped with a G to A substitution at nucleotide −119; a
point mutation responsible for hereditary persistence of
human AFP. This promoter has proved particularly useful
for transgene expression in low AFP producing hepatoma
cells [106]. Ishikawa et al have also shown that by placing
the AFP promoter/enhancer in the reverse orientation to
the long terminal repeats with a retroviral construct dra-
matically increases both HSV-tk transgene expression and
GCV-mediated cytotoxicity in a HepG2 tumour in vivo
[107]. The AFP promoter has also been used to drive CD
[108], IL-2 [109, 110], diphtheria toxin A [111], and in-
terestingly, a replication-competent adenovirus has been
constructed using the AFP promoter to drive an attenu-
ated E1B gene. Systemic delivery of this virus resulted in
tumour-speciﬁc regression [112]. The AFP promoter ac-
tivity can be weak, but it can be enhanced using Cre/loxP
technology to increase transgene expression [113], a sim-
ilar strategy to that applied to CEA.
ErbB2
ErbB2/HER2 is an oncogene that codes for a recep-
tortyrosinekinasethatisoverexpressedbytranscriptional
upregulation in approximately one third of breast and
pancreatic tumours, and in a small proportion of other
tumours. This promoter has been used to drive the ex-
pression of CD and when delivered using a retrovirus,
CD expression and signiﬁcant 5-FC-mediated cell death
was observed only in ErbB2-positive cell lines [114, 115].
ErbB2-drivenexpressionofamembranereceptor,murine
gastrin releasing peptide, has also been used eﬀectively to
target breast cancer cell lines with a radiolabelled peptide
[116]. More recently, studies to identify a minimal ErbB2
promoter were successful. Maeda et al [117] identiﬁed a
251bp fragment (−213/+38) that could direct transcrip-
tion of a luciferase reporter gene better than the SV40
immediate early promoter in breast cancer cells. When
linked to the HSV-tk gene, increased sensitivity to GCV
was observed in breast but not nonbreast cancer cell lines,
and suppressed the growth of these lines in nude mice.
MUC1/DF3
The MUC1 gene encodes a high molecular weight
mucin-like glycoprotein and is overexpressed at the tran-
scriptional level in breast and cholangiocarcinomas. A
114bp enhancer region has been identiﬁed that can mod-
ulate transcription from heterologous promoters [118].
DF3-positive breast cancer cell lines were more sensi-
tive to GCV-mediated cell killing when the HSV-tk gene
was delivered and driven by this enhancer. A replication-
defective adenovirus containing this construct was subse-
quently developed and inhibition of tumour growth was
observed in an intraperitoneal breast cancer metastases
model [119]. This strategy could transfect and kill car-
cinoma cells within haematopoetic stem cell populations
without causing associated normal tissue toxicity [120].
An adenovirus expressing BAX under the control of this
promoter has also been constructed for targeting ovarian
cancercelllinesexpressingDF3.Transgeneexpressionwas
restricted to tumour tissue in a nude mouse model and
administration of the virus 2–3days after tumour inocu-
lation eradicated > 99% of tumour implants [121].
Osteocalcin
Osteocalcin (OC) is a noncollagenous bone matrix
protein expressed at high levels in the neonate. It func-
tions primarily in osteoblasts found in growing bone and
is highly expressed in osteogenic sarcomas. Koeneman et
al[122]havealsoprovidedevidenceofexpressioninovar-
ian, lung, brain, and prostate tumours (especially those
showing androgen-independence). A phase I trial is now
underway to target androgen-independent prostate can-
cer using an adenoviral construct expressing HSV-tk un-
der the control of this promoter. Of all the transcrip-
tional targeting strategies discussed so far, the use of the
osteocalcin promoter has been tested thoroughly using
systemic delivery. Matsubara et al [123] have success-
fully constructed a replication-competent adenovirus us-
ing this promoter to drive E1a expression. They demon-
strated that 100% of mice carrying prostate xenografts
responded to systemic adenoviral delivery and more sig-
niﬁcantly 40% of mice were cured. Phase I/II trials are
now being carried out using the same virus to target
pulmonary metastases of osteosarcomas, following sys-
temic delivery of this virus, which must pass through
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S h i r a k a w ae ta l[ 125] also used an adenovirus to tar-
get osteosarcoma pulmonary metastases with an osteocal-
cin driven HSV-tk. In an established animal model, sys-
temic delivery of these constructs via tail vein injection
and subsequent intraperitoneal acyclovir treatment sig-
niﬁcantly decreased the number of tumour nodules in the
lung, while signiﬁcantly increasing the survival of these
animals. Interestingly, because the osteocalcin promoter
can also target bone stromal cells, which are important
for supporting the growth of prostate tumour metastases,
an adenovirus expressing HSV-tk under the control of
this promoter was eﬀective at destroying prostate cancer
xenografts in both subcutaneous and bone sites [122]. It
is quite clear that this promoter will be important for the
treatment of both prostate and osteosarcoma, but it will
besometimebeforewelearnaboutitstruespeciﬁcityand
any associated toxicities. Certainly, because this promoter
is eﬀective in androgen-independent prostate tumours, it
will ultimately be more eﬀective than the tissue-speciﬁc
PSA promoter discussed in the last section. A clearer un-
derstanding of this promoter may help to increase speci-
ﬁcity even further and Yeung et al have already identiﬁed
elements important for prostate speciﬁcity, in particular,
the elements important for androgen-independent speci-
ﬁcity [126].
L-plastin
L-plastin is constitutively expressed at high levels in
malignant epithelial cells, but is not expressed in nor-
mal tissue, except at low levels in haemopoetic cells. A
replication-incompetentadenovirushasbeenconstructed
to express either LacZ or CD under the control of the
human L-plastin promoter. High levels of expression of
β-galactosidase was seen in breast, ovarian, and ﬁbrosar-
coma cell lines [127] and in explants of ovarian cancer
cells from patients compared to normal mesothelial cells
from surgical specimens [128]. A greater reduction in tu-
mour size was seen when the adenovirus expressing CD
under the control of the L-plastin promoter was injected
into human ovarian tumour xenografts than when the
CD was controlled by the CMV promoter. L-plastin may
therefore be an eﬀective promoter for targeting ovarian
cancer.
Midkine
Midkine(MK)isaheparin-bindinggrowthfactorthat
is transiently expressed in the early stages of retinoic acid-
induced diﬀerentiation of embryonal carcinoma cells.
M a n ym a l i g n a n tt u m o u r se x p r e s sh i g hl e v e l so fM K
mRNA or protein with no expression in human liver.
This is important as adenovirus’ have a natural tropism
for liver and such promoters could be useful for pre-
venting transgene expression and associated hepatotoxi-
city in the liver. Miyauchi et al [129] examined the ex-
pression of MK in human oesophageal cancer cells. Pos-
itive staining with anti-MK antibody was found in 8 out
of 14 tumour specimens, while the surrounding normal
oesophageal tissues in these specimens were not stained.
The 5  ﬂanking 2.3-kbp region of the MK gene was then
used to drive the expression of HSV-tk, where expression
conferred the sensitivity to GCV. Since then, an adenovi-
ral vector has been constructed to express HSV-tk under
the control of the MK promoter to target Wilm’s tumour
and neuroblastoma cell lines [130]. Importantly, systemic
delivery of these constructs into mice resulted in much
lower hepatotoxicites; by day 8 of systemic delivery, four
out of ﬁve mice treated with an adenovirus expressing
HSV-tk via a CMV promoter had died, whereas all the
micetreatedwiththemidkineadenovirussurvivedatleast
10days[131].Themidkinepromoterhasalsoproveduse-
ful for targeting ovarian cancer cells and pancreatic cells,
as has the cyclooxygensae-2 gene promoter [132, 133].
Othertumour-type-speciﬁcpromoters
Many other tumour-speciﬁc promoters have been
utilised to target particular types and are listed in Table 2.
Particularly interesting is the secretory leukoprotease in-
hibitor gene (SPL1) promoter for targeting cervical carci-
noma cells [157], lung, breast oropharyngeal, bladder, en-
dometrial, and colorectal carcinomas [158]. Yamamura et
al[170]haveusedthepromoterfromthehumancalponin
gene, normally expressed in maturated smooth muscle
cells and overexpressed in human soft tissue and bone tu-
mour cells, to drive expression of ICP4, a major transact-
ing factor for viral genes to produce a novel condition-
ally replicating herpes simples virus. The viral treatment
showed stable and signiﬁcant inhibition of tumourigenic-
ity with cures in four out of ﬁve mice harbouring synovial
sarcoma, leimyosarcoma, and osteosarcoma cells, while
sparing normal vascular smooth muscle cells. Chen and
McCormick [172] report on a novel transcriptional tar-
geting strategy for colon cancer. Since many colon cancer
cells show mutations in either the adenomatous polypo-
sis coli or β-catenin genes that lead to stabilisation of β-
catenin and activation of downstream T-cell factor (Tcf)
target genes, tcf promoter elements were used to control
expression of an apoptosis gene, FADD, which appears to
eﬀectively and selectively kill colon cancer cells. The reg-
ulatory regions of the H19 gene, is diﬀerentially regulated
in normal and cancer cells and has been linked to diph-
theria toxin A or HSV-tk to successfully target syngeneic
bladder tumours in vivo with no obvious systemic toxi-
city towards the host animals [171]. A 2.2-kbp 5  ﬂank-
ing region of the human calretinin gene has been used
to drive the expression of HSV-tk selectively in mesothe-
lioma cell lines [174] and the human calcitonin promoter
has been used to drive expression of HSV-tk in medullary
thyroid carcinomas following systemic delivery by aden-
ovirus without any evident toxicity [175, 176, 177]. The
gastrin-releasing peptide gene promoter has been used to
selectively control HSV-tk expression in small-cell lung
cancer cells [167]; injection of an adenovirus contain-
ing this construct resulted in complete regression of lung118 T. Robson and D. G. Hirst 2003:2 (2003)
Table 2. Tumour-speciﬁc promoters.
Promoter Tumour target Reference
Telomerase
Lung, colon, ovarian, bladder, cervical, liver,
glioma [83,84,85,86,87,91,134,135,136,137]
CEA
Colorectal, pancreatic, cholangiocarcinoma,
breast, lung
[92, 93, 94, 95, 96, 97, 98, 100, 138, 139,
140, 141, 142, 143, 144]
Alpha feto protein (AFP) Hepatoma [64, 106, 107, 108, 145, 146, 147, 148,
149]
Erb B2 Breast, pancreatic, ovarian [114, 115, 116, 117, 150, 151, 152]
DF3/MUC1 Breast, choloangiocarcinoma [116, 118, 119, 120, 121, 153, 154]
Osteocalcin Prostate, ovary, lung, brain, osteoblasts [122, 123, 124, 125, 126, 127, 155, 156]
L-plastin Ovarian, breast, ﬁbrosarcoma [127, 128]
Midkine
Embryonal carcinoma; Wilm’s tumours,
neuroblastoma, pancreatic, oespohageal [129, 130, 131, 132, 133]
Secretory leukoprotease inhibitor
(SLP1)
Lung, breast, oropharyngeal, bladder,
endometrial, ovarian, colorectal, cervival [157, 158]
Alpha lactalbumin Breast [159]
Myc-max Breast, lung [140, 160, 161]
Somatostatin Malignant melanoma of soft parts [162]
Cox2 Ovarian, pancreatic, gastroin-testinal [132, 133, 163]
Ornithine decarboxylase Colon and neuroblastoma [164]
Epithelial glyocoprotein 2 (EPG2) Carcinomas [165]
c-Myb-responsive promoters Hematopoietic tumours [166]
Gastrin-releasing peptide Lung [167, 168]
Metallothionein Ovarian [169]
Calponin Soft tissue and bone tumours [170]
H19 Bladder [171]
Tcf Colon [172, 173]
Calretinin Mesothelioma [174]
Calcitonin/calcitonin gene-related
peptide Thyroid/thyroid medullary cancer [175, 176, 177]
Cell cycle-related
Cdc25C Melanoma [178]
CyclinA Melanoma [13, 178, 179]
Endoglin Endothelial cells [179, 180]
IGF-1-R Tumours mutant for p53, cMyb or EWS/WT1 [181]
E2F-1 Glioma [182]
tumour xenografts following IP administration of GCV
[168]. Lastly, Vandier et al [169] have been successful in
targetingcisplatin-resistantovariancarcinomacellswhich
overexpress the metallothionein gene, a metal binding
protein. The humanmetallothionein promoterwasthere-
fore used to drive expression of HSV-tk, resulting in
marked sensitisation to GCV in the cisplatin-resistant cell
lines compared to the cisplatin sensitive cells.
Cellcycle-relatedpromoters
The expression of proliferation-associated genes is a
hallmark of both cancer cells and tumour endothelial
cells. The retinoblastoma tumour suppressor gene (RB),
is a cell cycle-associated gene, which has the ability to
repress E2F-responsive promoters, such as E2F-1. E2F-
responsive promoters should therefore be more active in
tumour cells relative to normal cells because of an excess
of free E2F and loss of RB/E2F repressor complexes. Parr
et al [182] have shown that adenoviral vectors, contain-
ing transgenes driven by an E2F-1 promoter, can medi-
ate tumour-selective gene expression in vivo, allowing for
eradication of established tumours. Signiﬁcantly, less tox-
icity was seen with this adenovirus than standard consti-
tutively regulated adenoviral constructs.2003:2 (2003) Transcriptional Targeting in Cancer Gene Therapy 119
Table 3. Tumour environment-speciﬁc promoters.
Promoter Tumour target Reference
Endothelial cell-speciﬁc promoters
KDR/Flk-1 Sarcoma, ovarian, endothelioma [184, 185, 186, 187]
Flt-1 Breast, gynaecological, teratocarcinoma [188]
E-selectin Endothelioma [184, 186, 189]
von Willebrand factor (vWF) Endothelial cells [190]
Preproendothelin-1 Endothelial cells [191, 192, 193]
VCAM-1 Endothelial cells [186]
Hypoxia-responsivepromoters
VEGF (HRE elements) Hepatoma [145, 194, 195, 196, 197]
Erythropoetin (HRE elements) Brain [198]
Phosphoglycerate kinase 1 (HRE elements) Fibrosarcoma [33, 199]
Glucose-responsivepromoters
GRP78 Breast [198, 200, 201, 202, 203, 204, 205]
Hexokinase II Lung [206]
Muller’s group have published several papers where
the cell cycle-related promoter, cyclin A or cdc25c, has
beenusedincombinationwithatissue-speciﬁctyrosinase
promoter to selectively target proliferating melanoma
cells [13, 178]. These dual speciﬁcity promoters showed
> 20 fold and > 50 fold increase in cell cycle-related and
cell-type-speciﬁc regulation, respectively, and will be dis-
c u s s e di nm o r ed e t a i ll a t e r .
Finally, the insulin-like growth factor-1 (IGF-1) has
a central role in normal cellular proliferation. Transcrip-
tion of this gene is controlled by a number of tumour
suppressors. On the other hand, a number of oncogenes,
including mutant p53 and c-Myb and the fusion protein
EWS-WT1 signiﬁcantly stimulate promoter activity. This
promoter may therefore be a good candidate for use in
transcriptional targeting in cancer gene therapy protocols
[181].
Promotersthatrespondtothetumour
microenvironmentandphysiology
There are many aspects of the tumour microenviron-
ment that are unique, and can be targeted with strate-
gies that take advantage of genes upregulated in response
to these environments. For tumours to grow, they must
stimulate angiogenesis; this requires proliferation of en-
dothelial cells, a process speciﬁc (in normal adults) to the
tumour microenvironment. An additional bonus of this
strategy is that vectors delivered systemically will have di-
rect access to the proliferating endothelial cells of the tu-
mour vasculature. Furthermore, speciﬁc genes are upreg-
ulated in proliferating endothelial cells whose promoters
are attractive for targeting transgenes to the tumour vas-
culature. Secondly, because the tumour vasculature is of-
ten disorganised and inadequate, areas of low oxygen ten-
sion (hypoxia) are prevalent in malignant tumours [183].
Many genes transcriptionally upregulated in response to
hypoxia are mediated by the inducible transcription com-
plex, hypoxia-inducible factor-1 (HIF-1). HIF-1 binds to
DNA motifs known as hypoxia response elements (HREs)
within these genes. HREs can therefore be used to drive
transgene expression speciﬁcally within areas of tumour
hypoxia. It is extremely important to target this popula-
tion of cells since they are highly resistant to other forms
of treatment, such as radio and chemotherapy. Lastly, as
well as oxygen starvation, tumours can also be deprived
of glucose leading to the increased expression of genes
involved in glucose metabolism. The promoters of these
genes are therefore also being used to drive transgene ex-
pressionspeciﬁcallywithinatumour.Alistoftumourmi-
croenvironment and physiology-related promoters can be
found in Table 3.
Endothelialcell-speciﬁcpromoters
Over the past 10years a number of genes have been
reported to be upregulated in proliferating endothelium
of tumour blood vessels. The endothelial-speciﬁc kinase
insert domain receptor (KDR/ﬂk-1) and E-selectin have
been shown to be upregulated in tumour endothelium,
and deﬁned regions of these promoters have been used to
drive TNF-α carried by a retroviral vector. A 10–11-fold
increase in TNF-α expression within sEND endothe-
lioma cells was observed compared to NIH-3T3 ﬁbrob-
lasts [184]. More recently, it was demonstrated that the
KDR/ﬂk-1 promoter, is not only endothelial cell-speciﬁc,
but also active in two human ovarian cancer cell lines
where CD expression sensitised these cells to 5-FC both in
vitro and in vivo [185]. E-selectin expression is very low
in normal adult capillaries, but is signiﬁcantly elevated in
newly formed tumour vessels. It has been shown that the
E-selectin promoter is also activated by TNF-α, generat-
ing a 30-fold increase in transgene expression compared120 T. Robson and D. G. Hirst 2003:2 (2003)
to untreated cells. Furthermore, endothelial cells exposed
to tumour-conditioned medium as an in vitro simulation
of the tumour microenvironment resulted in even higher
induction of transgene expression [189].
Flt-1, a receptor for vascular endothelial growth fac-
tor (VEGF), is known to display dysregulated expression
in both tumour vasculature and tumour cells per se, and
adenoviral vectors containing transgenes under the con-
troloftheﬂt-1promoterachieveverylowlevelsoftoxicity
in normal liver. This is important, as this is the major or-
gan responsible for blood clearance of adenoviruses and
most at risk from inadvertent transgene-related toxicity.
Bauerschmitz et al [188] have shown that the ﬂt-1 pro-
moter is useful for the transcriptional targeting of aden-
oviruses to teratocarcinomas.
The promoter of human preproendothelin-1 has been
used to generate a retrovirus that demonstrates endothe-
lial-speciﬁc expression of the β-galactosidase gene [191,
192]. An adenovirus containing the preproendothelin-1
promoter driving luciferase expression has also been con-
structed. Following systemic injection, higher transgene
expression was seen using this promoter rather than a
CMV promoter, resulting in a high level of activity specif-
icallyinthenewvasculatureofprimarytumoursandlung
metastases, with the highest level in the angiogenic en-
dothelial cells of the metastasis [193]. However, an im-
pediment to the use of the preproendothelin-1 promoter
may be that it is also active in some epithelial cells [207],
compromising its vascular targeting speciﬁcity.
The promoter for human von Willebrand factor
(vWF) has also been used to drive transgene expression
selectively in proliferating endothelial cells [190, 208].
Both reports emphasise that although this promoter is
very weak, it appears to be highly selective for endothe-
lial cells and is eﬀective at suppressing endothelial cell
growth when driving the HSV-tk gene in the presence of
GCV.Furthermore,anovelstrategyhasbeendevelopedto
enhance this promoter > 14–100 fold while maintaining
> 30–100 fold speciﬁcity and will be discussed in more
detail later [208]. Nettelbeck also tested the PECAM-1,
endoglin, P-selectin, and KDR promoters, but vWF pro-
moter was clearly the most speciﬁc for endothelial cells.
Hypoxia-responsivepromoters
Hypoxia response elements (HREs) found within the
hypoxia-responsive genes of vascular endothelial growth
factor (VEGF), erythropoietin (Epo), and phosphoglyc-
erate kinase-1 (PGK-1), have been tested for their use in
cancer gene therapy. Shibata et al examined the HREs of
human VEGF and Epo and found high inducibility of
both in mammalian cells, while only the HREs from the
VEGF promoter were active in murine cells, and then to
a lesser extent than in human cells. In addition, the in-
troduction of multiple copies of the HRE and an E1B
minimal promoter improved the hypoxia responsiveness
[194]. Shibata then tested other HRE promoter com-
binations and found that 5HREs and a CMV minimal
promoter exhibited the most eﬀective hypoxia response
(over 500 fold) when compared to an intact CMV pro-
moter [195]. In addition, signiﬁcant antitumour eﬀects
were achieved with intraperitoneal injections of the pro-
drug, CB1954, in tumours that expressed bacterial ni-
troreductase (NTR) constitutively or via this hypoxia-
inducible promoter. Furthermore, respiration of 10% O2
increased tumour hypoxia in vivo and enhanced the an-
titumour eﬀects [196]. The HREs of the mouse VEGF
gene have also been used to construct a retroviral vec-
tor expressing HSV-tk and tumours expressing this con-
struct regressed following administration of GCV [197].
D a c h se ta l[ 199] have successfully utilised HREs from the
PGK-1geneandhaveshownthatitisactiveinhypoxictu-
mour cells in vivo and Ruan et al [198]h a v ec o n s t r u c t e d
an adeno-associated virus carrying HREs from the Epo
gene that can increase gene expression in brain tumour
cell lines, under anoxia, by 79–110 fold. Combinations
of both hypoxia and tumour/tissue-speciﬁc elements are
now being developed to increase speciﬁcity for hypoxic
tumour cells [145, 150, 186, 209]. These will be discussed
in more detail later.
Glucose-responsivepromoters
T h eg l u c o s e - r e g u l a t e dp r o t e i nG R P 7 8f u n c t i o n sa sa
molecular chaperone and can bind to malfolded pro-
teins and unassembled complexes. They are induced in
response to low glucose, hypoxia, acidic pH, or oxida-
tive stress, which are hallmark features of solid tumours.
The use of these promoters for cancer gene therapy was
ﬁrst proposed by Lee’s group [200]. This group has fully
characterised the use of this promoter in several tumour
systems. A truncated rat GRP78 promoter with most of
its distal basal elements removed drove high level expres-
sion in a murine ﬁbrosarcoma model [201]a n dw h e n
GRP78 was used in a retroviral system to drive HSV-tk,
HSV-tk expression levels were much higher [202]i nt u -
mours in vivo than cells in vitro, resulting in complete tu-
mour eradication with no recurrence of tumour growth.
Similarly, impressive results were obtained in a murine
mammary adenocarcinoma cell line (TSA) in syngeneic,
immune-competent hosts [203]; in addition, immune
memory was induced in these hosts with this system. Fi-
nally, Luna et al [204] have used photodynamic therapy
(PDT) to activate the GRP78 promoter, since this modal-
ity generates cytotoxic singlet oxygen species, which are
potent activators of this promoter. Inducible expression
of HSV-tk was observed after PDT in stably retroviral-
transduced mouse mammary carcinoma cells (TSA), and
enhancedtumouricidalactivitywasseen.TheGRP78pro-
moter is, therefore, also inducible and can function as a
molecular switch following exposure to PDT.
Hexokinase II is also overexpressed in solid tumours,
partly due to elevated glucose catabolism in rapidly pro-
liferating cells. Hexokinase II catalyses the ﬁrst commit-
ted step of glycolysis and is overexpressed in some tu-
mours since it is no longer responsive to the physiological2003:2 (2003) Transcriptional Targeting in Cancer Gene Therapy 121
Table 4. Exogenously controlled inducible promoters.
Promoter Tumour target Reference
Radiation-inducible promoters
Egr-1 and CArG elements Glioma, hepatocellular carcinoma, soft
tissue sarcomas
[209, 210, 211, 212, 213, 214, 215, 216,
217, 218, 219, 220, 221]
Waf-1 Murine ﬁbrosarcoma [222, 223]
RecA Clostridia [224, 225]
c-IAP2 Colon [226]
Heat-inducible promoters
HSP70B Breast, melanoma, and prostate [227, 228, 229, 230, 231, 232, 233, 234]
Gadd 153 [235]
Drug-inducible promoters
MDR-1 Breast, colon [236, 237, 238]
Tetracycline inducible Breast, melanoma, brain, glioma,
prostate
[49, 146, 239, 240, 241, 242, 243, 244,
245, 246, 247]
Rapamycin inducible Fibrosarcomas [248]
Tamoxifen-inducible estrogen response elements Breast [150, 249, 250]
inhibitor, glucagon. Adenovirus carrying LacZ under the
control of the hexokinase promoter showed preferential
β-galactosidase expression in nonsmall cell lung carcino-
mas compared to primary normal human bronchial ep-
ithelial cells. Cells infected with an adenovirus express-
ing HSV-tk under the control of this promoter, demon-
strated selective toxicity, with a 10 to 100-fold increase
in IC50 between the lung cancer cell lines and the nor-
mal bronchial epithelial cells and a 100-fold increase in
theIC50whencomparedtoMCF-7breastcarcinomacells
[206].
EXOGENOUSLY CONTROLLED INDUCIBLE
PROMOTERS
The use of tissue/tumour-speciﬁc cellular promoters
to restrict transgene expression usually results in consti-
tutive expression in the target tissue. However, in many
situations it might be preferable to exogenously regulate
the duration and level of expression. A list of exogenously
controlled inducible promoters currently being used for
cancer gene therapy purposes can be found in Table 4.
Radiation-induciblepromoters
Radiation therapy is one of the main strategies used
to treat solid tumours and although successful in some
cases, there is the potential for enhancing radiation ef-
fectsbycombiningwithotheragentssuchasgenetherapy.
Radiation-mediated gene therapy exploits the fact that as
well as the cell killing eﬀect, radiation will also activate
transgenes which are driven by a radiation-inducible pro-
moter. Conﬁnement of transcription to the radiation ﬁeld
should be achievable by either using conformal, intersti-
tial,orbrachytherapyandbytargeteddeliveryofradioiso-
topes. The cellular response to ionising radiation includes
the transcriptional activation of a variety of genes, for ex-
ample, c-jun, NFB, EGR1, and p21WAF1/CIP1,t on a m eb u t
a few. However, although numerous radiation-inducible
genes and proteins have been identiﬁed, relatively few
radiation-inducible promoters/enhancers have been fully
characterised.
Datta et al [251] identiﬁed a sequence of the EGR-
1 gene that confers radiation inducibility. This sequence,
CC(A+T rich)GG, is known as the radiation-responsive
CArG element. In vitro studies, using the CArG, ele-
ments of the EGR1 promoter have demonstrated a dose-
dependent expression of reporter gene activity of up to
28 fold following radiation exposure (0–20 Gy) [210].
However, at therapeutically relevant doses of radiation
(2 Gy) only a 3-fold increase in reporter gene activity
was achievable [211]. The thymidine analogue 5-iodo-
2 -deoxyuridine radiolabelled with the Auger electron-
emitter iodine-125 also activated the promoter and re-
sulted in increased β-galactosidase activity in the 9L
gliosarcoma tumour model in vivo. A number of stud-
ies have used CArG elements to drive expression of TNF
using liposomes [212], a haemopoetic cell carrier [213]
and adenovirus [214, 215, 216] .T h e s es t u d i e sh a v el e dt o
clinical trials where an adenovirus carrying TNF driven
by CArG elements of the Egr-1 promoter are injected
intratumourally into patients with soft-tissue sarcomas,
followed by irradiation [217]. Enhanced antitumour ef-
fects were also observed when the Egr-1 promoter was
combined with HSV-tk [210, 252]. Tumours regressed
signiﬁcantly after GCV and radiation in comparison to
GCV alone. Furthermore, tumour regrowth did not oc-
cur when GCV treatment was withdrawn. As well as be-
ing radiation-inducible the Egr-1 promoter was tumour-
speciﬁc for hepatocellular carcinomas whereas its expres-
sion was barely detectable within normal liver [210]. It122 T. Robson and D. G. Hirst 2003:2 (2003)
was evident from some of these papers that reporter gene
expression was detectable in nonirradiated cells, which
could limit its use in combination with cytotoxic agents.
Weichselbaum et al [218] are also developing a her-
pes simplex virus (HSV-1) that is induced to prolifer-
ate within the tumour volume following ionising radia-
tion exposure. Finally, Marples and Scott are developing
a novel molecular switch using CArG elements derived
from this promoter, in combination with a Cre/loxP site-
speciﬁc recombination system of the P1 bacteriophage, to
generate high level and constitutive expression of trans-
genes following activation by therapeutically relevant ra-
diation doses [209, 219, 253]. This system will be dis-
c u s s e di nm o r ed e t a i ll a t e r .
The promoter of the P21WAF1/CIP1 gene is also
radiation-sensitive and its activation is also increased in
tumour cells [254, 255, 256, 257, 258, 259, 260, 261]. In-
terestingly, expression appears to be independent of p53
status in a variety of tumour types [257, 262, 263]. Fur-
thermore, we have evidence that this promoter is also
highly active following exposure of cell in vitro to hy-
poxia (unpublished data, 2002). This promoter therefore,
may have several layers of speciﬁcity, that is, tumour-,
radiation-, and hypoxia-speciﬁc. Research in our labora-
tory has shown that WAF-1 can successfully drive expres-
sion of inducible nitric oxide synthase which leads to the
generation of the vasoactive, cytotoxic, and radiosensitis-
ing product, nitric oxide (NO), close to therapeutically
relevant doses. As well as causing signiﬁcant vasorelax-
a t i o ni ni s o l a t e da r t e r i e s[ 222], it also caused abundant
apoptosis in a murine ﬁbrosarcoma model and a highly
signiﬁcant tumour growth delay in vivo when used in
combination with 20 Gy radiation [223]. This promoter
is also being used to drive expression of cytochrome P450
enzymes to increase the activation of the bioreductive
drug, AQ4N [264, 265].
Radiation-inducible bacterial promoters have also
been used such as RecA, delivered using the anaerobic
apathogenic bacterium, clostridia, as a gene transfer sys-
tem to target anoxic areas within tumours. Signiﬁcant in-
creases in β-galactosidase activity and TNF-α secretion
was seen following 2-Gy irradiation [224, 225, 266]; frac-
tionation of the radiation dose lead to repeated gene in-
duction.
Lastly, a retrovirus gene trap screening identiﬁed c-
IAP2 as an X-ray-inducible gene with radiation-sensitive
NFkB binding sites. Construction of a plasmid with four
tandem repeats of the NFkB binding site driving the ex-
pression of the apoptotic suicide gene BAX,r e s u l t e di n
signiﬁcant cell kill following a therapeutically relevant
dose of 2-Gy X-rays [226].
Heat-induciblepromoters
Hyperthermia is known to improve the response of
tumours to radiation and chemotherapeutic treatment
[267]. The cellular response to hyperthermia is associated
with the synthesis of heat shock proteins (HSP). Strate-
gies are now being developed to combine hyperthermia
with gene therapy by using the promoter of the HSP70B
gene to selectively activate therapeutic transgenes follow-
ing hyperthermia treatment, thereby controlling the lo-
cation, duration, and level of expression of the therapeu-
tic transgene. MRI-guided ultrasound is also being used
to accurately focus gene activation [227]. The HSP70B
promoter has been used to drive expression of TGF-β in
an adenoviral construct [268]; HSV-tk, where sensitivity
to GCV in a mouse mammary cancer cell line was in-
creased more than 50,000 times [228]; HSV-tk/cytosine
deaminase fusion gene and a replication-competent E1B-
attenuated adenoviral vector [229]; and IL-12 in com-
bination with radiation [230, 231]. The HSP70B pro-
moter appears to be highly active and a 200–950-fold in-
crease in reporter gene expression was observed when ad-
ditional heat shock elements (HSE) were introduced to
the HSP70 promoter with a 1–2◦C decrease in the ac-
tivation temperature [232]. Two very elegant constructs
have now been developed which incorporate elements
from the HSP70 promoter. Emiliusen et al and Lipinski
et al have developed constructs which incorporate eﬀec-
tive feedback loops which can enhance transgene expres-
s i o na n di m m u n er e s p o n s e[ 14] or inhibit transgene ex-
pression in normal cells expressing wild-type p53 [173].
These will be discussed in more detail later. Interestingly,
electromagnetic ﬁelds have been reported to activate the
HSP70 promoter and could possibly be used as switches
to regulate transgenes for cancer gene therapy purposes
[269]. This has already been achieved with another stress-
inducible promoter, Gadd153. The promoter from this
gene was placed upstream of the TNF-α gene and de-
livered using magnetite cationic liposomes (MCLs). In
nude mice, these constructs induced cell death through-
out much of the tumour area on heating under an alter-
nating magnetic ﬁeld as a result of a 3-fold increase in
TNF-α production compared with that of a nonheated
tumour [235].
Drug-induciblepromoters
As already mentioned many tissue/tumour-speciﬁc
promoters are often weak and are therefore less eﬀective
than constitutive promoters. Much work has therefore fo-
cused on developing promoters which are both strong
and regulatable exogenously. The use of tetracycline (tc)-
responsive promoters is probably best researched. Two
systems exist; the allosteric-oﬀ system or the allosteric-
on system which have been described in detail by Har-
rington et al [78]. A tc inducible promoter has been used
to drive expression of HSV-tk in breast carcinoma cells
and increased the IC50 for GCV by 50 fold, although by-
stander eﬀects were not enhanced [239]. Both IL-2 and
IL-1β converting enzyme (ICE) have been shown to be
tightly regulated, respectively, in human melanoma cells
[240] and in a rat brain tumour model [241] in vivo using
asimilarapproach.However,therealbeautyofthissystem
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certain tissues by combining with tissue/tumour-speciﬁc
promoters. A replication-incompetent adenovirus, which
has the glial ﬁbrillary acidic protein coupled to a mini-
malCMVpromoter,hasbeenconstructedtodriveexpres-
sion of a tc-controlled transactivator. High levels of ex-
pression were reported in cells of glial origin and expres-
sion was tightly controlled by the addition of tc. This sys-
tem is both glial-speciﬁc and allows for repression of ec-
topic gene expression [49]. Both a parvovirus and an ade-
novirushavebeenconstructedtocombinecell-typespeci-
ﬁcity with high-level regulated expression for prostate tis-
sues using the ARR2BP promoter [57]o rf o rh e p a t o m a
cells using a liver-speciﬁc promoter [146]. In a similar
study,Rubinchiketal[242]haveplacedthetctransactiva-
tor gene under the control of the ARR2PB promoter and
an FASL fusion gene under the control of a tc responsive
promoter, within a single construct. Not only is the ex-
pression of this apoptotic related gene FASL restricted to
prostate cancer cells and is regulatable by the tc analogue,
doxycycline, but also, in vivo studies conﬁrmed that sys-
temic delivery of this vector was well tolerated at doses
that were lethal for the FASL controlled by a CMV pro-
moter. Overall, tc promoters show high-level inducibility
compared to other inducible promoters and when com-
bined with other tissue- and tumour-speciﬁc elements,
they can be highly inducible and speciﬁc.
Dimerisation switch-on systems are also being devel-
oped, which make use of the immunosuppressive agent,
rapamycin, and again this area has been reviewed by Har-
rington et al [78]. Rapamycin has been used to control
regulation of adenoviral vectors where inhibition of tu-
mour growth was seen following subcutaneous injection
into the human ﬁbrosarcoma, HT1080 [248].
As well as tc, there is now much interest in the use of
estrogen response elements (EREs) which are responsive
to estrogens and can be controlled by antiestrogens, such
as tamoxifen. EREs have been used to drive expression of
the E1a and E4 units in response to estrogens-generating
conditionally replicative adenoviruses, selective for ER-
positive breast cancer cells, which can also be modulated
bytheadditionoftamoxifen[249].WhentheseEREswere
combined with hypoxia response elements, these viruses
cankillER-positivebreastcancercellsorcellsgrowingun-
der hypoxic conditions [150].
Lastly, a series of papers have described the use of
the multidrug resistance (mdr1) gene promoter which
harbours drug-inducible response elements to drive ex-
pression of a reporter gene [270]a n dT N F - α within a
retroviral construct both in vitro in mammary and colon
carcinoma cell lines [271] and in vivo in MCF-7 mam-
mary xenografts [236]. Chemotherapy regulation by dox-
orubicin or vincristine showed a 25-fold increase in TNF-
α secretion within the xenografts and was more eﬀec-
tiveininhibitingtumourgrowththanconstitutivelyTNF-
α-expressing vectors. More recently, Walther et al [237]
have shown that the mdr1 promoter also harbours heat-
inducible elements.
STRATEGIES FOR ENHANCING THE EFFICIENCY
OF WEAK TISSUE/TUMOUR-INDUCIBLE
PROMOTERS
The transcriptional activity of the tissue-speciﬁc ele-
ments used as promoters for gene therapy is often too
weak to generate adequate concentrations of transgene
product in target cells. The dilemma is how to achieve
high levels of transgene expression without compromis-
ing speciﬁcity. As mentioned previously, several elegant
strategies have been developed which combine both in-
ducible and tissue/tumour-speciﬁc elements, thereby in-
creasing transcriptional activation while allowing tissue
speciﬁcity to be retained. Furthermore, other systems
have been developed which are tissue-speciﬁc but also
highly active by encouraging positive feedback loops in-
corporating strong transcriptional activators.
In one approach, a weak tissue-speciﬁc promoter
(vWF or gastrointestinal-speciﬁc sucrose-maltase) initi-
ates transcription of both the transgene and a gene en-
coding a VP16-LexA fusion protein (Figure 2). This pro-
tein, in turn, interacts with LexA binding sites inserted
upstreamofthetissue-speciﬁcpromoter,leadingtotrans-
activation and enhanced transcription. Repeated cycles of
this ampliﬁcation lead to very high levels (14–100 fold)
of tissue-speciﬁc expression [208]. An alternative strategy
using a GAL4/VP16 fusion protein to enhance the weak
tumour-speciﬁc CEA promoter achieved similar ampli-
ﬁcation of the reporter genes LacZ or GV16 [100]. This
concept has been further developed by using a tissue-
speciﬁc promoter (PSA) to drive expression of GAL4
derivatives fused with up-to-4 VP16 activation domains.
By incorporating up-to-5 GAL4 binding sites upstream
of the reporter gene (ﬁreﬂy luciferase) 800-fold ampliﬁ-
cation was achieved [272].
The Cre/loxP system oﬀers a diﬀerent approach to
the enhancement of tissue-speciﬁc promoter activity
(Figure 3). Target cells are transfected with a plasmid in-
corporating the therapeutic transgene separated from a
strong constitutive promoter by a “stop” cassette enclosed
by two loxP sites. Cotransfection with a site-speciﬁc Cre
gene driven by the tissue-speciﬁc promoter generates Cre,
which excises the stop cassette, bringing the therapeutic
transgene under the control of the constitutive promoter
[113]. This system has been used to achieve therapeutic
levels of transgenes in mouse tumours in vivo with a high
degree of tissue speciﬁcity. CEA-driven expression of Cre
together with expression of lox-HSV-tk caused signiﬁ-
cant suppression of tumours in mice treated with GCV,
without signiﬁcant side eﬀects [99, 104]. CEA-driven ex-
pression of Cre also achieved cytotoxicity in tumours
in mice transfected with cytosine deaminase and dosed
with the 5-FU precursor, 5-FC, and this was reﬂected
in enhanced overall survival. Diphtheria toxin (DT) has
also been used therapeutically in growth hormone (GH)-
producing pituitary tumours; the DT gene was activated
via the Cre/loxP system driven by the GH promoter [273].
Cre/loxP has also been used to increase HSV-tk transgene124 T. Robson and D. G. Hirst 2003:2 (2003)
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Figure 2. Schematic outline of a positive feedback loop utilising VP16/LexA to enhance weak promoters. Transcription is initiated by
the cell-type-speciﬁc promoter in target cells which leads to expression of the VP16/LexA fusion protein. The VP16/LexA protein then
interacts with the LexA binding sites upstream of a possible second cell-type-speciﬁc promoter leading to transactivation and thus
enhancement of transcription. Alternatively, the VP16/LexA fusion protein could be expressed along with the transgene expressed via
an IRES. Adapted from Nettelbeck et al [179].
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Figure 3. The Cre recombinase/loxP system for enhancing weak tissue or tumour-speciﬁc promoters. Cre, induced by the speciﬁc
promoter excises the transcriptional stop cassette via the loxP sites. This brings the therapeutic transgene under the control of a strong
constitutive promoter (eg, CMV).
expression following expression of Cre via the radiation-
inducible CArG elements [209, 219].
Another approach that has a potential for tumour-
speciﬁc activation incorporates speciﬁcity for mutated
p53[173].Inthisstudy,adoublerecombinantadenovirus
consisting of two independent expression cassettes was
constructed; one controlled expression of the E. coli
nitroreductase gene via an hsp70 promoter containing
Lac1 binding sites, which was capable of binding a p53-
inducible lac repressor, incorporated into the second ex-
pression cassette. This resulted in growth inhibition of
human tumour xenografts with mutated p53 following
exposure to the prodrug, CB1954, but not in tumours
with wild-type p53 status.
Lastly, high-level tissue-speciﬁc expression of a di-
rectly cytotoxic protein, gibbon ape leukemia virus hy-
perfusogenic envelope protein (GALV-FMG), has been
achieved in melanoma cells by elegantly driving both
GALV and the gene for heat shock factor 1 (HSF-1)
from a human tyrosinase promoter, preferentially acti-
vated in melanoma cells [14]. Promoter activity initiates
low-level expression of the toxic transgene, but also HSF-
1, which binds to a heat shock binding element upstream
of the tyrosinase promoter. This enhances promoter2003:2 (2003) Transcriptional Targeting in Cancer Gene Therapy 125
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Figure 4. A transcriptional feedback loop for tissue-speciﬁc expression of highly cytotoxic genes which incorporate an immunostim-
ulatory component. A weak tissue- or tumour-speciﬁc promoter will initially express the therapeutic transgene (TG) at low levels,
however coexpression of the heat shock transcription factor (HSF-1) will activate the heat shock element (HSE) causing progressively
increased TG and HSF-1 expression via a positive feedback loop. In addition, the expression of HSF-1 causes an immune response.
Adapted from Emiliusen et al [14].
activation and completes the transcriptional feedback
loop (Figure 4). This strategy has achieved long-term
eradication of melanomas in mice [14].
CONCLUSIONSAND FUTURE PERSPECTIVES
The ultimate goal of all currently used cancer therapy
is to target damaging events to tumour cells while sparing
normal tissues suﬃciently that they can recover to an ade-
quatefunctionallevel;thisappliesequallytogenetherapy.
However, while conventional therapies rely on one, or at
the most two, targeting characteristics such as spatial de-
position, biochemical pathway speciﬁcity, or cellular pro-
liferation,thereisnotheoreticallimittothenumberofel-
ements that canbe incorporated into a gene therapy strat-
egytoconfertumourspeciﬁcity.Thereisalsothepotential
for controlling temporal expression of transgene products
in tumours much more precisely than the concentration
of conventional anticancer agents.
The ﬁrst opportunity for targeting speciﬁcity is at the
level of vector delivery. There is currently an immense
amount of research activity in this area (beyond the scope
of this review) reﬂecting the recognition that advances in
this process are critical to unleashing the potential of all
the recent developments in transcriptional control. Direct
injection systems have been important in providing the
proof of principle for several gene therapy strategies, but
however sophisticated these may become, the number of
accessible sites will always be limited and perhaps more
importantly the crucial problem of disseminated disease
cannot be addressed.
As detailed in this review, the possibilities for tar-
geting via transcriptional control are endless. It is un-
likely for most cancers that any one promoter will oﬀer
the ideal combination of interrelated characteristics: high
level speciﬁcity to endogenous or exogenous factors, si-
lenceintheabsenceofthesefactorsandsuﬃcientstrength
to induce the therapeutic transgene many fold. In any
event, the use of a single promoter/transgene combina-
tion fails to exploit one of the main advantages of gene
therapy: the ability to custom design, even within a sin-
gleplasmid,acombinationofdiverseelementsthatconfer
exquisite spatial and temporal speciﬁcity for an individual
tumour type. It may even be possible using gene/protein
array technology to tailor this speciﬁcity to an individual
patient’s tumour. It could be envisaged that promoters
speciﬁc to the tumour tissue type could be combined
with factors inducible by the tumour microenvironment
and/or exogenous control elements (eg, radiation). This
has already been successfully achieved in vivo by combin-
ing cell cycle and tyrosinase promoters [179], HREs and
KDR/E- selectin promoters [186], and HREs and the AFP
promoter [145]. Furthermore, these could be combined
with elements incorporating strong promoters/enhancers
in positive feedback loops giving progressively stronger
and more speciﬁc transgene expression [14, 179]o rb y
using a Cre/loxP system [274]. The packaging of such
complex constructs, ideally within a single construct, will126 T. Robson and D. G. Hirst 2003:2 (2003)
require a more thorough understanding of the control
domains from individual promoters such that multiple
copies of the elements that confer tumour speciﬁcity can
be incorporated while eliminating those sequences that
permit expression in nontarget tissues.
A vital issue when considering the clinical application
of any gene therapy protocol is the basal expression of the
transgene. Many of the papers discussed in this review
have failed to adequately assess basal-level expression in
other tissues following systemic delivery in an appropri-
ate in vivo model. Highly sensitive systems now exist for
assessing promoter leakiness in vitro [42] and recent de-
velopments in imaging technology have permitted whole
animal detection of ﬂuorescent reporter gene products in
small rodents [272, 275]. Although this technology is the-
oreticallyapplicableinman,considerablecautionmustbe
exercised in extrapolating from animal data. It is likely in
early trials that transgene activation by a given promoter
combination will need to be assessed using a nontoxic re-
porter gene, particularly where tissue-speciﬁc promoters
are to be used. This use of a surrogate marker is an addi-
tional and important advantage of gene therapy over con-
ventional chemotherapy that can be applied even at the
level of the individual patient.
Finally, the therapeutic transgene product will usually
be an enzyme, so the opportunity arises to achieve addi-
tional speciﬁcity at the level of enzyme biochemistry or
enzyme product characteristics. For example, reductive
enzymes can metabolise bioreductive prodrugs, such as
AQ4N [264, 265] or tirapazamine [276], speciﬁcally in a
hypoxic environment thereby adding an additional layer
of tumour speciﬁcity even after transductional and tran-
scriptional targeting. A similarly enhanced speciﬁcity can
be achieved, wherethe ﬁnal product of the enzyme specif-
ically sensitises hypoxic tumour cells [222, 223]. Alterna-
tively, a powerful approach for tight regulation has been
to make the activity of the apoptotic target gene, E2F1,
tamoxifen-dependent by fusing it to the ligand-binding
domain of the estrogen receptor; massive apoptosis was
seen upon activation by tamoxifen [277].
The rate of development of gene therapy over the
past decade has been dramatic and if this continues, it
is reasonable to speculate that the next decade will see
widespread introduction of this new technology to clin-
ical practice. We can anticipate a level of anticancer eﬃ-
cacy combined with normal tissue sparing that few small
molecules have yet achieved and with the current ad-
vances in systemic gene delivery this is a very real pos-
sibility. By combining the very best of cancer gene ther-
apy strategies with current chemotherapy and radiother-
apy treatment regimens, real patient beneﬁt with reduced
toxicities should be achievable.
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